On April 20, 2025, the "Beyond Limits" Cancer Patients Rehabilitation Rally was officially launched across China. Organized by the Cancer Rehabilitation Society of CACA , and supported by Hengrui Pharmaceuticals, the initiative harnesses digitization and other cutting-edge technologies to enhance long-term survival rates and quality of life for cancer patients.

China has achieved remarkable advancements in its cancer prevention and treatment infrastructure in recent years. While substantial improvements have been made, key challenges remain, particularly regarding the equitable allocation of premium medical resources and strengthening primary-level healthcare services. The nationwide “Beyond Limits” initiative welcomes participation from all tiers of medical institutions, clinical teams, and corporate partners. The program advocates for the adoption of digital health technologies and internet-based platforms to provide standardized, evidence-based care. This innovative approach is designed to optimize rehabilitation outcomes while facilitating the decentralization of specialized oncology resources to community-level facilities, ultimately working toward eliminating healthcare disparities and realizing true health equity.

The initiative focuses on three key breakthroughs: First, it transcends geographical constraints through telemedicine and digital platforms to enable nationwide access to premium medical resources; second, it overcomes technical barriers by integrating AI and big data analytics into clinical workflows to enable standardized diagnosis and treatment; third, it addresses cost challenges by establishing a full-cycle digital patient management system that significantly reduce temporal, financial, and operational burdens, making quality care more accessible, affordable and sustainable.

The first phase of the program will focus on three major cancer types—prostate cancer, breast cancer, and hematologic malignancies—covering nearly 20 provinces/municipalities and benefiting thousands of patients. Beyond providing essential services such as disease education, psychological support, and medication guidance, the program will also pilot innovative tools such as remote monitoring and AI-powered follow-ups through a dedicated digital management platform.